Lukes A - Search Results

1

Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial.

Peaceman AM, Andrews WW, Thorp JM, Cliver SP, Lukes A, Iams JD, Coultrip L, Eriksen N, Holbrook RH, Elliott J, Ingardia C, Pietrantoni M. Peaceman AM, et al. Among authors: lukes a. Am J Obstet Gynecol. 1997 Jul;177(1):13-8. doi: 10.1016/s0002-9378(97)70431-9. Am J Obstet Gynecol. 1997. PMID: 9240576 Clinical Trial.

2

A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.

Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HO, Li Y, McKain L, Arjona Ferreira JC, Langenberg AG, Wagman RB, Stewart EA. Al-Hendy A, et al. Among authors: lukes as. Pain Manag. 2023 Apr;13(4):205-211. doi: 10.2217/pmt-2022-0085. Epub 2023 May 15. Pain Manag. 2023. PMID: 37183454 Free article. Review.

3

Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor.

Lukes AS, Thorp JM Jr, Eucker B, Pahel-Short L. Lukes AS, et al. Am J Obstet Gynecol. 1997 Mar;176(3):639-41. doi: 10.1016/s0002-9378(97)70561-1. Am J Obstet Gynecol. 1997. PMID: 9077620

4

Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.

James AH, Lukes AS, Brancazio LR, Thames E, Ortel TL. James AH, et al. Am J Obstet Gynecol. 2004 Aug;191(2):449-55. doi: 10.1016/j.ajog.2004.03.009. Am J Obstet Gynecol. 2004. PMID: 15343220

5

Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.

Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, Schulmann T, Marsh EE. Stewart EA, et al. Among authors: lukes as. Am J Obstet Gynecol. 2024 Feb;230(2):237.e1-237.e11. doi: 10.1016/j.ajog.2023.10.030. Epub 2023 Oct 18. Am J Obstet Gynecol. 2024. PMID: 37863160 Free article. Clinical Trial.

6

von Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine system.

Lukes AS, Perry S, Ortel TL. Lukes AS, et al. Obstet Gynecol. 2005 May;105(5 Pt 2):1223-6. doi: 10.1097/01.AOG.0000157758.94890.59. Obstet Gynecol. 2005. PMID: 15863590

7

Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.

Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, Richter HE, Eder SE, Attia GR, Patrick DL, Rubin A, Shangold GA. Lukes AS, et al. Obstet Gynecol. 2010 Oct;116(4):865-875. doi: 10.1097/AOG.0b013e3181f20177. Obstet Gynecol. 2010. PMID: 20859150 Clinical Trial.

8

A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding.

Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. Freeman EW, et al. Among authors: lukes a. Am J Obstet Gynecol. 2011 Oct;205(4):319.e1-7. doi: 10.1016/j.ajog.2011.05.015. Epub 2011 May 14. Am J Obstet Gynecol. 2011. PMID: 21777897 Clinical Trial.

9

Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.

Liu JH, Soper D, Lukes A, Gee P, Kimble T, Kroll R, Mallick M, Chan A, Gillard P, Harrington A, Sniukiene V, Shulman LP. Liu JH, et al. Among authors: lukes a. Obstet Gynecol. 2018 Nov;132(5):1241-1251. doi: 10.1097/AOG.0000000000002942. Obstet Gynecol. 2018. PMID: 30303900 Clinical Trial.

10

Lukes AS, Soper D, Harrington A, Sniukiene V, Mo Y, Gillard P, Shulman L. Lukes AS, et al. Obstet Gynecol. 2019 May;133(5):869-878. doi: 10.1097/AOG.0000000000003211. Obstet Gynecol. 2019. PMID: 30969201 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters